Who
Douglas E. Williams
Director
Company insider
Files Form 4 as: Director, CAMP4 Therapeutics; Director, Climb Bio; EVP & President, R&D, Sana Biotechnology; President & CEO, Codiak BioSciences; Director, Ovid Therapeutics; Director, Ironwood Pharmaceuticals; Director, Regulus Therapeutics; EVP Research & Development, Biogen.
In numbers
- Trades disclosed
- 134
- Buys
- 5
- Sells
- 7
- Bought
- $100K
- Sold
- $3.8M
- Companies
- 12
- Companies where not an officer
- 8
- First trade
- 5 Jan 2006
- Last trade
- 10 Jun 2026
- Last filed
- 12 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Jun 2026filed 12 Jun 2026 | CAMP CAMP4 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —28,000 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | CAMP CAMP4 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —28,000 at $0.00 | filing |
| 5 Jun 2026filed 8 Jun 2026 | CLYM Climb Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 5 Jun 2026filed 8 Jun 2026 | CLYM Climb Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 4 Jun 2025filed 5 Jun 2025 | CLYM Climb Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 31 Mar 2025filed 1 Apr 2025 | CLYM Climb Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —78,873 at $0.00 | filing |
| 17 Mar 2025filed 19 Mar 2025 | CAMP CAMP4 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,787 at $0.00 | filing |
| 11 Nov 2024filed 12 Nov 2024 | CLYM Climb Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 11 Nov 2024filed 12 Nov 2024 | CLYM Climb Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —6,291 at $0.00 | filing |
| 7 Mar 2024filed 8 Mar 2024 | SANA Sana Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —67,083 at $0.00 | filing |
| 7 Mar 2024filed 8 Mar 2024 | SANA Sana Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —301,875 at $0.00 | filing |
| 2 Nov 2023filed 3 Nov 2023 | SANA Sana Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 10 Apr 2023filed 11 Apr 2023 | SANA Sana Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,100,000 at $0.00 | filing |
| 28 Mar 2023filed 30 Mar 2023 | Codiak BioSciences | SEC FORM 4 Sold | $7,50041,667 at $0.18 | filing |
| 17 Feb 2023filed 21 Feb 2023 | Codiak BioSciences | SEC FORM 4 Sold | $4,5327,681 at $0.59 | filing |
| 16 Feb 2023filed 21 Feb 2023 | Codiak BioSciencesoption or derivative | SEC FORM 4 Code M | —22,969 at $0.00 | filing |
| 16 Feb 2023filed 21 Feb 2023 | Codiak BioSciences | SEC FORM 4 Code M | —22,969 | filing |
| 24 Jan 2023filed 26 Jan 2023 | Codiak BioSciencesoption or derivative | SEC FORM 4 Code A | —465,000 at $0.00 | filing |
| 20 Jan 2023filed 23 Jan 2023 | Codiak BioSciences | SEC FORM 4 Sold | $2,9445,075 at $0.58 | filing |
| 19 Jan 2023filed 23 Jan 2023 | Codiak BioSciencesoption or derivative | SEC FORM 4 Code M | —13,667 at $0.00 | filing |
News
Ovid Therapeutics (NASDAQ:OVID) and Perrigo (NYSE:PRGO) Head to Head ReviewOVID · themarketsdaily.com · 20 Oct 2026Biogen (NASDAQ:BIIB) Hits New 52-Week High Following Analyst UpgradeBIIB · dailypolitical.com · 14 Oct 2026Biogen (BIIB) vs Amgen (AMGN) and Gilead (GILD): Which Big Pharma Stock is a Better Buy?BIIB · insidermonkey.com · 13 Oct 2026Ovid Therapeutics (NASDAQ:OVID) Stock Rated "Overweight" in New Coverage at Cantor FitzgeraldOVID · dailypolitical.com · 12 Oct 2026
0 headlines in the last 90 days name Douglas E. Williams; 4 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.